This roundtable series gauges the use of combination CD19 inhibition and chemotherapy in the previously treated diffuse large B-cell lymphoma setting, as discussed by participants at virtual live events.
Considering Alternatives to CAR T-Cell Therapy for Primary Refractory DLBCL
June 20th 2022During a live virtual event, Jakub Svoboda, MD, discussed with participants the choice of therapy for a patient with relapsed/refractory diffuse large B-cell lymphoma who would not receive stem cell transplant or chimeric antigen receptor therapy.
When to Use Second-Line CAR T-cell Therapy for Relapsed/Refractory DLBCL
March 24th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Gilles Salles, MD, discussed when to use CAR T-cell therapy in the second-line setting for patients with relapsed/refractory diffuse large B-cell lymphoma and the outcomes of trials of these agents. This is the first of 2 articles based on this event.
Reviewing Key Efficacy and Safety Data for Tafasitamab Plus Lenalidomide in DLBCL
April 14th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Gilles Salles, MD, discussed the study results and practical considerations for the use of tafasitamab plus lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.
Long-Term Combination Data Show Most Benefit in Second-Line DLBCL
May 16th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Stephen A. Schuster, MD, discussed the 5-year outcomes of the L-MIND trial of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.
Physicians Respond to 5-Year Tafasitamab/Lenalidomide Data for R/R DLBCL
June 6th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Stephen J. Schuster, MD, discussed the use of tafasitamab plus lenalidomide in patients with diffuse large B-cell lymphoma including managing adverse events and treating patients after disease progression.
Treatment Considerations in Primary Refractory vs Early-Relapsed DLBCL
July 25th 2023In the first article of a 2-part series, Joseph M. Tuscano, MD, discusses at a virtual live event with fellow clinicians how to define early-relapsed or primary refractory diffuse large B-cell lymphoma and how this impacts treatments for this patient population.
Updated Data Show Efficacy of Tafasitamab/Lenalidomide in R/R DLBCL
November 28th 2023In the first article of a 2-part series, Hayder Saeed, MD, discusses the 5-year follow up data from the L-MIND study, which shows the continuing efficacy of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.
Tafasitamab/Lenalidomide in R/R DLBCL Shows Benefit with Long-Term Use
December 26th 2023In the second article of a 2-part series, Hayder Saeed, MD, discusses the long-term use of tafasitamab and lenalidomide in patients with diffuse large B-cell lymphoma and how the combination therapy compares in the real-world setting.
Breaking Down Considerations for Tafasitamab/Lenalidomide in DLBCL
January 24th 2024In the first part of a 2-article series, Matthew A. Lunning, DO, FACP, takes into consideration the perspectives of his peers on the use of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.
What is the Best Dose of Lenalidomide? Lunning Provides His Analysis in R/R DLBCL
February 16th 2024In the second part of a 2-article series, Matthew A. Lunning, DO, FACP, leads a discussion on how to best manage toxicities from tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.